Monchana Jullangkoon
Overview
Explore the profile of Monchana Jullangkoon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
97
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chittrakarn S, Siripaitoon P, Kositpantawong N, Kanchanasuwan S, Aiewruengsurat D, Bintachitt P, et al.
Am J Trop Med Hyg
. 2024 Apr;
110(6):1223-1229.
PMID: 38688263
Melioidosis is a potentially fatal infection caused by the bacterium Burkholderia pseudomallei. Septic arthritis caused by this infection is uncommon and difficult to treat. The role of adjunctive open arthrotomy...
2.
Boonpeng A, Jaruratanasirikul S, Jullangkoon M, Samaeng M, Wattanavijitkul T, Bhurayanontachai R, et al.
Antimicrob Agents Chemother
. 2022 Oct;
66(11):e0084522.
PMID: 36226944
Several pathophysiological changes can alter meropenem pharmacokinetics in critically ill patients, thereby increasing the risk of subtherapeutic concentrations and affecting therapeutic outcomes. This study aimed to characterize the population pharmacokinetic...
3.
Jaruratanasirikul S, Neamrat P, Jullangkoon M, Samaeng M
Pharmacotherapy
. 2022 Jul;
42(8):659-666.
PMID: 35789108
Study Objective: The aim of this study was to investigate the impact of therapeutic plasma exchange (TPE) on the plasma concentrations and pharmacokinetic (PK) patterns of meropenem. Design: Prospective, open-label,...
4.
Jaruratanasirikul S, Thengyai S, Wongpoowarak W, Wattanavijitkul T, Tangkitwanitjaroen K, Sukarnjanaset W, et al.
Antimicrob Agents Chemother
. 2015 Mar;
59(6):2995-3001.
PMID: 25753628
Pathophysiological changes during the early phase of severe sepsis and septic shock in critically ill patients, resulting in altered pharmacokinetic (PK) patterns for antibiotics, are important factors influencing therapeutic success....
5.
Jaruratanasirikul S, Wongpoowarak W, Jullangkoon M, Samaeng M
J Pharmacol Sci
. 2015 Mar;
127(2):164-9.
PMID: 25727953
The aims of this study were to i) reveal the population pharmacokinetics; and ii) assess the probability of target attainment (PTA) and cumulative fraction of response (CFR) (defined as the...
6.
Jaruratanasirikul S, Kositpantawong N, Jullangkoon M, Aeinlang N, Wongpoowarak W
J Med Assoc Thai
. 2013 Dec;
96(10):1283-9.
PMID: 24350408
Background: Pharmacokinetic changes have been found in critically ill patients, including ventilator-associated pneumonia (VAP) when compared with healthy volunteers leading to fluctuation of plasma concentrations. Objective: To compare the probability...
7.
Jaruratanasirikul S, Aeinlang N, Jullangkoon M, Wongpoowarak W
J Med Assoc Thai
. 2013 Jun;
96(5):551-7.
PMID: 23745309
Background: Drug dispositions are altered in critically ill patients, including ventilator-associated pneumonia (VAP) when compared with healthy subjects leading to fluctuations of plasma concentrations. Objective: To compare the probability of...
8.
Jaruratanasirikul S, Wongpoowarak W, Aeinlang N, Jullangkoon M
Antimicrob Agents Chemother
. 2013 May;
57(7):3441-4.
PMID: 23650160
The aim of this study was to reveal population pharmacokinetics and assess the efficacies of various dosage regimens of sulbactam in terms of the probability of target attainment with this...
9.
Jaruratanasirikul S, Wongpoowarak W, Kositpantawong N, Aeinlang N, Jullangkoon M
Int J Antimicrob Agents
. 2012 Sep;
40(5):434-9.
PMID: 22959555
Several pathophysiological changes in critically ill patients are important in determining the therapeutic success of β-lactam antibiotics. The aim of this study was to assess the population pharmacokinetics and probabilities...
10.
Jaruratanasirikul S, Limapichat T, Jullangkoon M, Aeinlang N, Ingviya N, Wongpoowarak W
Int J Antimicrob Agents
. 2011 Jul;
38(3):231-6.
PMID: 21726984
The bactericidal activity of β-lactams is determined by the time that concentrations in tissue and serum are above the minimum inhibitory concentration (T>MIC) for the pathogen. The aim of this...